Evotec (NASDAQ:EVO - Get Free Report) is anticipated to post its Q4 2024 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Evotec to post earnings of ($0.11) per share and revenue of $215.09 million for the quarter.
Evotec Stock Performance
Shares of Evotec stock traded down $0.12 on Monday, reaching $4.17. 23,799 shares of the company were exchanged, compared to its average volume of 127,477. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $3.62 and a 200 day moving average of $4.14. Evotec has a one year low of $2.84 and a one year high of $5.68.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th.
View Our Latest Stock Analysis on EVO
Institutional Investors Weigh In On Evotec
An institutional investor recently raised its position in Evotec stock. Bank of America Corp DE raised its holdings in shares of Evotec SE (NASDAQ:EVO - Free Report) by 262.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,828 shares of the company's stock after buying an additional 9,289 shares during the quarter. Bank of America Corp DE's holdings in Evotec were worth $53,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
